Phospho-soda solution for oral administration fl. 45ml # 2

Latin name

Fleet Phospho-soda

Release form

Oral solution.

Packaging

2 bottles of 45 ml.

pharmachologic effect

Phospho-soda is a saline laxative, the action of which is based on an increase in water retention in the lumen of the small intestine using osmotic processes.

The accumulation of fluid in the ileum leads to increased peristalsis and subsequent bowel cleansing.

Indications

Preparation for endoscopic or X-ray examination of the colon, preparation for surgery on the colon.

Contraindications

hypersensitivity to drug components

partial or complete intestinal obstruction

violation of the integrity of the intestine

megacolon (congenital or acquired)

acute inflammatory bowel disease

heart failure

renal failure

nausea, vomiting, abdominal pain

children and adolescents up to 15 years old.

Application during pregnancy and lactation

Do not use Fleet Phospho-soda during pregnancy, since there is insufficient reliable information about the drug's ability to toxicly affect the fetus and / or cause its malformation.

Since sodium phosphate is excreted in breast milk, you should stop breastfeeding immediately after taking the first dose of the drug and within the next 24 hours after taking the last dose.

special instructions

Fleet Phospho-Soda is not used to treat constipation.

It is used with caution in elderly and debilitated patients, patients with reduced renal function, heart disease, colostomy, as well as in patients on a diet low in salt, as there is a possibility of hyperphosphatemia, hypocalcemia, hypokalemia, dehydration against the background of hypernatremia and acidosis ...

The patient should be warned about the expected frequent loose stools. Very rarely, with endoscopy on the mucous membrane of the sigmoid and rectum, single or multiple aphtho-like changes were observed. These were either lymphoid follicles, or discrete formations of an inflammatory nature, or changes in the epithelium caused by the preparation. These abnormalities are not clinically significant and disappear spontaneously without treatment. Rarely, there is a prolongation of the QT interval on the ECG as a result of electrolyte imbalance such as hypocalcemia or hypokalemia.

Use with caution in individuals taking calcium channel blockers, diuretics, lithium-based drugs and other medications that can affect electrolyte levels, since there is a possibility of hyperphosphatemia, hypocalcemia, hypokalemia, dehydration associated with hypernatremia and acidosis.

During the period of taking the drug, the absorption of drugs in the gastrointestinal tract may be delayed or even completely stopped.

The effect of regularly taken drugs (eg, oral contraceptives, antiepileptic drugs, antidiabetic drugs, antibiotics) may be reduced or absent altogether.

Structure

1 bottle (45 ml) contains:

Active substances: sodium hydrogen phosphate dodecahydrate 240 mg (10.8 g)

sodium dihydrogen phosphate dihydrate 542 mg (24.4 g)

component of the composition without quantity

Excipients: glycerol 99%

sodium saccharin

sodium benzoate (E211)

ginger and lemon flavoring (ginger oil, alcohol, lemon oil, partially stabilized lemon oil, citric acid, water)

purified water.

Method of administration and dosage

Fleet Phospho-soda is prescribed for adults and adolescents over 15 years of age.

For elderly patients, doses similar to those for adults are used.

You should start taking the drug on the day preceding the prescribed procedure.

If the procedure is scheduled before noon, the instructions for the morning appointment must be followed.

If the procedure is scheduled for the afternoon, then the instructions for the daily appointment must be followed.

Morning appointment.

The day before the procedures

Dosage

240mg / ml + 542mg / ml x 45ml

Storage conditions and periods

At a temperature not higher than 25 degrees.

Expiration date: 3 years

INN / Active ingredient

Sodium hydrogen phosphate dodecahydrate + sodium dihydrogen phosphate dihydrate

Specifications

Category

Laxatives

Scope of the drug

Gastrointestinal tract

Release form

Solution

Manufacturer country

Spain

Package quantity, pcs

2

Vacation conditions

Without recipe

Brand name

Casen Recordati, S.L., Spain ES

The amount of the dosage form in the primary package

45 ml

Primary packaging type

Bottle

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Laxative

Anatomical and therapeutic characteristics

A06AD17 Sodium phosphate

Dosage form

Oral solution

The target audience

Adult

Expiration date in days

1095

Package weight, g

one hundred

Dosage (volume) of the substance in the preparation

:

sodium dihydrogen phosphate dihydrate 542 mg, sodium hydrogen phosphate dodecahydrate 240 mg